Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
8.01% $3.10
America/New_York / 26 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 3.63 mill |
EPS: | -12.97 |
P/E: | -0.240 |
Earnings Date: | May 14, 2024 |
SharesOutstanding: | 1.171 mill |
Avg Daily Volume: | 0.0249 mill |
RATING 2024-04-26 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Sell | |
P/E: | Neutral | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Ebit | ||||||
Asset | ||||||
Debt | n/a | n/a | n/a | n/a | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.240 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.04x |
Company: PE -0.240 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$7.81 (151.78%) $4.71 |
Date: 2024-04-26 |
Expected Trading Range (DAY) |
---|
$ 2.62 - 3.58 ( +/- 15.55%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-29 | Singh Vanila | Buy | 25 000 | Stock Option (right to buy) |
2024-01-29 | Shah Vinay | Buy | 112 000 | Stock Option (right to buy) |
2024-01-29 | Jambulingam Thani | Buy | 25 000 | Stock Option (right to buy) |
2024-01-29 | Mathias Sheila | Buy | 112 000 | Stock Option (right to buy) |
2024-01-29 | Dubin Michael F | Buy | 25 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
75.08 |
Last 71 transactions |
Buy: 2 396 200 | Sell: 387 701 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $3.10 (8.01% ) |
Volume | 0.0052 mill |
Avg. Vol. | 0.0249 mill |
% of Avg. Vol | 20.87 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and VRP324, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.